If a crisis were to suddenly arise for your organization, would your people be ready to handle it?
Although the diabetes pipeline is not large, we continue to have progress in meeting the unmet needs of patients with diabetes.
Payers and providers have traditionally operated on opposite sides of the tracks with limited collaboration, resulting in a disjointed and complicated experience for patients when accessing care.
A deeper dive into the proposed payer mergers reveals how they could impact market dynamics.
Health policy experts generally agree that properly tailored transparency tools can help to hold down prices. What is not settled at this point is what transparency should look like.
In this commentary, attorney Nathaniel Lacktman shares why, in the era of payment reform, it is critical for health plans to provide telemedicine reimbursement.
Those who are in decision-making roles must study how other countries address healthcare financing and delivery so as to bring the best initiatives of the studied country to the healthcare systems they oversee.
Health policy experts generally agree that properly tailored transparency tools can help to hold down prices. What is not settled at this point is what transparency should look like.
Consumer and provider expectations have changed as a result of the digital economy. Here are four reasons why payers need to start migrating their businesses in that direction.
Biopharmaceutical manufacturers’ at-risk day is coming. Here’s how to prepare.
To put more risk-based dollars in the bank, payers need to master a new level of gathering and reporting on not just claims data, but clinical data as well.
Hospitals and physicians must be diligent in the implementation of their meaningful use business or strategic plan.
The Comprehensive Care for Joint Replacement (CCJR), has organizations’ leadership wondering how they will be able to perform in such a model. Here are some tips.
Today’s value-focused economy was a primary discussion point at a recent roundtable of health plan CEOs. The discussion led to five essential attributes that organizations must embrace to thrive.
Clinically Integrated Networks (CINs) are evolving quickly across the country in response to changing reimbursement trends and the move to value-based payments.
Clinically Integrated Networks (CINs) are evolving quickly across the country in response to changing reimbursement trends and the move to value-based payments.
This might be the year when it becomes clear, perhaps painfully so, whether or not biosimilars can deliver on cost savings expectations.
Tips to help healthcare executives present their most authentic selves during remote interviews.
Federal antitrust officials are determining how, and if, transactions will move forward. Here's a roadmap of what's ahead in 2016.
The solution to succeeding in value-based reimbursement models is to start inside the hospital with high acuity patients and build the systems that support them.
Innovation will be necessary to compete for consumers in the new market environment. Using data effectively can help plans stand out.
While forming risk-based entities among Medicaid providers could be an effective way to better manage the care of low-income populations, the risk of unintended consequences cannot be ignored. A key hedge against these consequences is better use of patient data.
Here are four critical considerations that are integral to successful implementation of a value-based payment model.
Unnecessary diagnostic tests are harmful to patients and costly for health plans.
Since posting its lowest annual growth rate in more than six years, the average cost of healthcare services accelerated in May and June.
Sometimes in our technology-driven environment, we get into a fixed routine of the current standard of care for our patients. What would we see or hear if we saw our practice or facility through the eyes and ears of our patients?
The hope is that more biosimilars will lead to more access and more affordable medications, but biosimilar uptake is lagging. Here’s why and how FDA hopes to fix it.
Healthcare providers have increasingly entered into value-based contracts with payers in recent years because they offer the opportunity to increase revenue-the primary driver of change for any business.